- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
December 2, 2024Robins Kaplan LLP Announces 2025 Partners
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
New ANDA Cases
Fall 2013
Case Name |
Date Filed |
Judge |
Drug |
Patent |
Alpex Pharma., S.A. v. Zydus Pharma. USA, Inc., 13-4076 (D.N.J.) |
July 1, 2013 |
Hon. Noel L. Hillman |
Suprenza®(phentermine hydrochloride tablets) |
6,149,938 |
Purdue Pharma L.P. v. Teva Pharma. USA, Inc., 13-4606 (S.D.N.Y.) |
July 2, 2013 |
Hon. Sidney H. Stein |
OxyContin®(oxycodone hydrochloride) |
8,337,888 8,309,060 |
Novartis AG v. Accord Healthcare, Inc. USA, 13-1013 (D.D.C.) |
July 3, 2013 |
Hon. Emmet G. Sullivan |
Myfortic®(mycophenolate sodium delayed-release tablets) |
6,025,391 6,172,107 6,306,900 |
Aptalis Pharma US Inc. v. Mylan Pharma., Inc., 13-4158 (D.N.J.) |
July 5, 2013 |
Hon. Mary L. Cooper |
Canasa®(mesalamine rectal suppository) |
8,217,083 8,436,051 |
Apotex Corp. v. Alcon Research Ltd., IPR2013-00428 (PTAB) |
July 5, 2013 |
N/A |
Travatan Z®(travoprost ophthalmic solution) |
8,268,299 |
Apotex Corp. v. Alcon Research Ltd., IPR2013-00429 (PTAB) |
July 5, 2013 |
N/A |
Travatan Z®(travoprost ophthalmic solution) |
8,323,630 |
Apotex Corp. v. Alcon Research Ltd., IPR2013-00430 (PTAB) |
July 5, 2013 |
N/A |
Travatan Z®(travoprost ophthalmic solution) |
8,388,941 |
Par Pharma., Inc. v. Takeda Pharma. Co., Ltd., 13-3151 (N.D. Cal.) |
July 9, 2013 |
Hon. Elizabeth D. Laporte |
Dexilant®(dexlansoprazole delayed-release capsules) |
8,461,187 |
Brigham and Women’s Hospital, Inc. v. Perrigo Co., 13-11640 (D. Mass.) |
July 9, 2013 |
Hon. Rya W. Zobel |
Pepcid Complete®(famotidine / magnesium hydroxide / calcium carbonate tablets) |
5,229,137 |
UCB, Inc. v. Accord Healthcare, Inc., 13-1206 (D. Del.) |
July 10, 2013 |
Hon. Leonard P. Stark |
Vimpat®(lacosamide tablets) |
RE38,551 |
UCB, Inc. v. Alembic Pharma. Ltd., 13-1207 (D. Del.) |
July 10, 2013 |
Hon. Leonard P. Stark |
Vimpat®(lacosamide tablets) |
RE38,551 |
UCB, Inc. v. Amneal Pharma, LLC, 13-1208 (D. Del.) |
July 10, 2013 |
Hon. Leonard P. Stark |
Vimpat®(lacosamide tablets) |
RE38,551 |
UCB, Inc. v. Apotex Corp., 13-1209 (D. Del.) |
July 10, 2013 |
Hon. Leonard P. Stark |
Vimpat®(lacosamide tablets) |
RE38,551 |
UCB, Inc. v. Aurobindo Pharma Ltd., 13-1210 (D. Del.) |
July 10, 2013 |
Hon. Leonard P. Stark |
Vimpat®(lacosamide tablets) |
RE38,551 |
UCB, Inc. v. Breckenridge Pharma., Inc., 13-1211 (D. Del.) |
July 10, 2013 |
Hon. Leonard P. Stark |
Vimpat®(lacosamide tablets) |
RE38,551 |
UCB, Inc. v. Glenmark Generics Inc., USA., 13-1212 (D. Del.) |
July 10, 2013 |
Hon. Leonard P. Stark |
Vimpat®(lacosamide tablets) |
RE38,551 |
UCB, Inc. v. Hetero USA Inc., 13-1213 (D. Del.) |
July 10, 2013 |
Hon. Leonard P. Stark |
Vimpat®(lacosamide tablets) |
RE38,551 |
UCB, Inc. v. Mylan Pharma. Inc., 13-1214 (D. Del.) |
July 10, 2013 |
Hon. Leonard P. Stark |
Vimpat®(lacosamide tablets) |
RE38,551 |
UCB, Inc. v. Ranbaxy Labs. Ltd., 13-1215 (D. Del.) |
July 10, 2013 |
Hon. Leonard P. Stark |
Vimpat®(lacosamide tablets) |
RE38,551 |
UCB, Inc. v. Sandoz, Inc., 13-1216 (D. Del.) |
July 10, 2013 |
Hon. Leonard P. Stark |
Vimpat®(lacosamide tablets) |
RE38,551 |
UCB, Inc. v. Sciegen Pharma., Inc., 13-1217 (D. Del.) |
July 10, 2013 |
Hon. Leonard P. Stark |
Vimpat®(lacosamide tablets) |
RE38,551 |
UCB, Inc. v. Sun Pharma Global FZE, 13-1218 (D. Del.) |
July 10, 2013 |
Hon. Leonard P. Stark |
Vimpat®(lacosamide tablets) |
RE38,551 |
UCB, Inc. v. Watson Labs., Inc.--Florida, 13-1219 (D. Del.) |
July 10, 2013 |
Hon. Leonard P. Stark |
Vimpat®(lacosamide tablets) |
RE38,551 |
UCB, Inc. v. Zydus Pharma (USA), Inc., 13-1220 (D. Del.) |
July 10, 2013 |
Hon. Leonard P. Stark |
Vimpat®(lacosamide tablets) |
RE38,551 |
Alcon Pharma. Ltd. v. Lupin Ltd., 13-1230 (D. Del.) |
July 12, 2013 |
Hon. Sue L. Robinson |
Moxeza®(moxifloxacin hydrochloride ophthalmic solution) |
8,450,311 |
Cumberland Pharma. Inc. v. Akorn, Inc., 13-1232 (D. Del.) |
July 12, 2013 |
Hon. Leonard P. Stark |
Acetadote®(acetylcysteine injection) |
8,148,356 |
Aptalis Pharma US Inc. v. Sandoz Inc., 13-4290 (D.N.J.) |
July 12, 2013 |
Hon. Mary L. Cooper |
Canasa®(mesalamine rectal suppository) |
8,217,083 8,436,051 |
Abbvie, Inc. v. Roxane Labs., Inc., 13-0708 (S.D. Ohio) |
July 18, 2013 |
Hon. Edmund A. Sargus |
Norvir® |
8,268,349 8,399,015 |
Merck & CIE v. Watson Labs., Inc., 13-1272 (D. Del.) |
July 23, 2013 |
Hon. Richard G. Andrews |
Beyaz®(drospirenone / ethinyl estradiol / levomefolate calcium tablets) |
6,441,168 |
Merck & CIE v. Watson Labs., Inc., 13-1309 (D. Nev.) |
July 23, 2013 |
Hon. James C. Mahan |
Beyaz®(drospirenone / ethinyl estradiol / levomefolate calcium tablets) |
6,441,168 |
Cornerstone Therapeutics Inc. v. Exela Pharma Sciences, LLC, 13-1275 (D. Del.) |
July 24, 2013 |
Hon. Gregory M. Sleet |
Cardene®(nicardipine hydrochloride premixed injection) |
7,612,102 7,659,291 |
Eisai Co., Ltd. v. Glenmark Pharma., Ltd., 13-1279 (D. Del.) |
July 24, 2013 |
Hon. Leonard P. Stark |
Banzel®(rufinamide tablets) |
6,740,669 7,750,028 8,076,362 |
Eisai Co., Ltd. v. Hetero Labs Ltd., 13-1280 (D. Del.) |
July 24, 2013 |
Hon. Leonard P. Stark |
Banzel®(rufinamide tablets) |
6,740,669 7,750,028 8,076,362 |
Eisai Co., Ltd. v. Lupin Ltd., 13-1281 (D. Del.) |
July 24, 2013 |
Hon. Leonard P. Stark |
Banzel®(rufinamide tablets) |
6,740,669 7,750,028 8,076,362 |
Eisai Co., Ltd. v. Mylan Pharma. Inc., 13-1282 (D. Del.) |
July 24, 2013 |
Hon. Leonard P. Stark |
Banzel®(rufinamide tablets) |
6,740,669 7,750,028 8,076,362 |
Eisai Co., Ltd. v. Roxane Labs., Inc., 13-1284 (D. Del.) |
July 24, 2013 |
Hon. Leonard P. Stark |
Banzel®(rufinamide tablets) |
6,740,669 7,750,028 8,076,362 |
Janssen Pharma., Inc. v. Actavis Elizabeth LLC, 13-4507 (D.N.J.) |
July 25, 2013 |
Hon. Claire C. Cecchi |
Nucynta®and Nucynta®ER (tapentadol hydrochloride extended-release tablets) |
RE39,593 7,994,364 8,309,060 |
Alcon Research, Ltd. v. Mylan Pharma. Inc., 13-1332 (D. Del.) |
July 26, 2013 |
Hon. Sue L. Robinson |
Travatan Z®(travoprost ophthalmic solution) |
8,268,299 8,323,630 8,388,941 |
Depomed, Inc. v. Banner Pharmacaps Inc., 13-4542 (D.N.J.) |
July 26, 2013 |
Hon. Jose L. Linares |
Zipsor®(diclofenac potassium capsules) |
6,365,180 7,662,858 7,884,095 7,939,518 8,110,606 |
UCB, Inc. v. Sun Pharma Global FZE, 13-5514 (N.D. Ill.) |
Aug. 1, 2013 |
Hon. Amy J. St. Eve |
Vimpat®(lacosamide tablets) |
RE38,551 |
Pfizer Inc. v. Wockhardt Bio AG, 13-1387 (D. Del.) |
Aug. 2, 2013 |
Hon. Gregory M. Sleet |
Toviaz®(fesoterodine fumarate extended-release tablets) |
6,858,650 7,384,980 7,855,230 7,985,772 8,338,478 |
Novartis Pharma. Corp. v. Hospira, Inc., 13-4669 (D.N.J.) |
Aug. 2, 2013 |
Hon. Susan D. Wigenton |
Zometa®(zoledronic acid) |
7,932,241 8,324,189 |
Supernus Pharma., Inc. v. Actavis Inc., 13-4740 (D.N.J.) |
Aug. 7, 2013 |
Hon. Renee M. Bumb |
Oxtellar XR®(oxcarbazepine extended-release tablets) |
7,722,898 7,910,131 |
Depomed, Inc. v. Banner Pharmacaps Inc., 13-0653 (M.D.N.C.) |
Aug. 9, 2013 |
Hon. James A. Beaty, Jr. |
Zipsor®(diclofenac potassium capsules) |
6,365,180 7,662,858 7,884,095 7,939,518 8,110,606 |
AstraZeneca AB v. Wockhardt Ltd., 13-4854 (D.N.J.) |
Aug. 12, 2013 |
Hon. Joel A. Pisano |
Nexium®(esomeprazole magnesium delayed-release oral capsules) |
5,714,504 5,877,192 6,875,872 |
Novo Nordisk Inc. v. Amneal Pharma., LLC, 13-4915 (D.N.J.) |
Aug. 14, 2013 |
Hon. Michael A. Shipp |
Vagifem®(estradiol vaginal tablets) |
7,018,992 |
Teva Branded Pharma. Products R&D, Inc. v. Perrigo Pharma. Co., 13-1441 (D. Del.) |
Aug. 16, 2013 |
Hon. Gregory M. Sleet |
ProAir®HFA (albuterol sulfate inhalation aerosol) |
7,105,152 7,566,445 6,446,627 8,132,712 |
Reckitt Benckiser Pharma., Inc. v. Par Pharma., Inc., 13-1461 (D. Del.) |
Aug. 20, 2013 |
Hon. Richard G. Andrews |
Suboxone®(buprenorphine hydrochloride / naloxone hydrochloride sublingual film) |
8,475,832 8,017,150 |
Purdue Pharma. Products L.P. v. TWI Pharma, Inc., 13-5003 (D.N.J.) |
Aug. 20, 2013 |
Hon. Jose L. Linares |
Intermezzo®(zolpidem tartrate sublingual tablets) |
8,242,131 8,252,809 |
Novartis Pharma. Corp. v. Par Pharma., Inc., 13-1467 (D. Del.) |
Aug. 22, 2013 |
Hon. Richard G. Andrews |
Exelon®Patch (rivastigmine transdermal system or extended release film) |
6,335,031 |
Purdue Pharma. Products L.P. v. TWI Pharma, Inc., 13-5999 (N.D. Ill.) |
Aug. 22, 2013 |
Hon. Thomas M. Durkin |
Intermezzo®(zolpidem tartrate sublingual tablets) |
8,242,131 8,252,809 |
Intelgenx Corp. v. Wockhardt Bio, AG, 13-5074 (D.N.J.) |
Aug. 23, 2013 |
Hon. William J. Martini |
Forfivo XL®(bupropion hydrochloride extended-release tablets) |
7,674,479 |
Horizon Pharma AG v. Watson Labs., Inc.—Florida, 13-5124 (D.N.J.) |
Aug. 26, 2013 |
Hon. Joseph E. Irenas |
Rayos®(prednisone delayed-release tablets) |
6,488,960 6,677,326 8,309,124 8,168,218 8,394,407 |
Novartis Pharma. Corp. v. Akorn, Inc., 13-5125 |
Aug. 26, 2013 |
Hon. Susan D. Wigenton |
Zometa®(zoledronic acid for injection) Reclast® (zoledronic acid for injection) |
7,932,241 9,052,987 8,324,189 |
Horizon Pharma AG v. Watson Labs., Inc.—Florida, 13-61868 (S.D. Fl.) |
Aug. 28, 2013 |
Hon. Robert N. Scola, Jr. |
Rayos®(prednisone delayed-release tablets) |
6,488,960 6,677,326 8,309,124 8,168,218 8,394,407 |
Takeda Pharma. Co., Ltd. v. Mylan, Inc., 13-4001 (N.D. Cal.) |
Aug. 28, 2013 |
Hon. Nathanael M. Cousins |
Dexilant®(dexlansoprazole capsules) |
8,173,158 8,173,187 |
Takeda Pharma. Co., Ltd. v. Mylan, Inc., 13-4002 (N.D. Cal.) |
Aug. 28, 2013 |
Hon. Nathanael M. Cousins |
Dexilant®(dexlansoprazole capsules) |
6,462,058 6,664,276 6,939,971 7,285,668 7,790,755 |
Senju Pharma. Co., Ltd. v. Akorn, Inc., 13-6080 (S.D.N.Y.) |
Aug. 28, 2013 |
Hon. Paul A. Crotty |
Istalol® |
6,335,335
|
Genzyme Corp. v. Dr. Reddy’s Labs., Ltd., 13-1506 (D. Del.) |
Aug. 29, 2013 |
Hon. Gregory M. Sleet |
Mozobil®(plerixafor solution for injection) |
RE42,152 7,897,590 6,987,102 |
Genzyme Corp. v. Sandoz, Inc., 13-1507 (D. Del.) |
Aug. 29, 2013 |
Hon. Gregory M. Sleet |
Mozobil®(plerixafor solution for injection) |
RE42,152 7,897,590 6,987,102 |
Genzyme Corp. v. Teva Pharma. USA, Inc., 13-1508 (D. Del.) |
Aug. 29, 2013 |
Hon. Gregory M. Sleet |
Mozobil®(plerixafor solution for injection) |
RE42,152 7,897,590 6,987,102 |
Takeda Pharma. Co., Ltd. v. Mylan, Inc., 13-0197 (N.D.W.V.) |
Aug. 29, 2013 |
Hon. Irene M. Keeley |
Dexilant®(dexlansoprazole capsules) |
6,462,058 6,664,276 6,939,971 7,285,668 7,790,755 8,173,158 8,173,187 |
Takeda Pharma. USA, Inc. v. Par Pharma. Companies, Inc., 13-1524 (D. Del.) |
Aug. 30, 2013 |
Hon. Sue L. Robinson |
Colcrys®(colchicine tablets) |
7,906,519 7,935,731 8,093,298 7,964,648 8,093,297 |
Roche Palo Alto LLC v. Mylan Pharma. Inc., 13-1532 (D. Del.) |
Sept. 4, 2013 |
Hon. Gregory M. Sleet |
Valcyte®(valganciclovir hydrochloride tablets) |
6,083,953 |
Roche Palo Alto LLC v. Watson Labs., Inc.—Florida, 13-1533 (D. Del.) |
Sept. 4, 2013 |
Hon. Gregory M. Sleet |
Valcyte®(valganciclovir hydrochloride tablets) |
6,083,953 |
Ferring B.V. v. Actavis, Inc., 13-0477 (D. Nev.) |
Sept. 6, 2013 |
Hon. Larry R. Hicks |
Lysteda®(tranexamic acid tablets) |
8,487,005 7,947,739 8,022,106 8,273,795 |
Alkem Labs. Ltd. v. NPS Pharma., Inc., 13-6487 (N.D. Ill.) |
Sept. 10, 2013 |
Hon. Edmond E. Chang |
Nucynta ER®(tapentadol extended-release tablets) |
6,071,970 |
Merck, Sharp & Dohme Corp. v. Aurobindo Pharma Ltd., 13-5442 (D.N.J.) |
Sept. 11, 2013 |
Hon. Jerome B. Simandle |
Sustiva®(efavirenz tablets) |
6,639,071 6,939,964 6,673,372 |
Jazz Pharma., Inc. v. Amneal Pharma., LLC, 13-5450 (D.N.J.) |
Sept. 12, 2013 |
Hon. Esther Salas |
Xyrem® |
8,457,988 8,461,203 |
Alcon Research, Ltd. v. Wockhardt Ltd., 13-1452 (S.D. Ind.) |
Sept. 12, 2013 |
Hon. Sarah Evans Barker |
Pataday®(olopatadine hydrochloride ophthalmic solution) |
6,995,186 7,402,609 |
AbbVie Inc. v. Hikma Pharma. Co., Ltd., 13-1557 (D. Del.) |
Sept. 13, 2013 |
Hon. Gregory M. Sleet |
Zemplar®(paricalcitol injectable) |
5,597,815 |
Eli Lilly and Co. v. Sun Pharma Indus. Ltd., 13-1469 (S.D. Ind.) |
Sept. 13, 2013 |
Hon. Tonya Walton Pratt |
Alimta®(pemetrexed injectable) |
7,772,209 |
Senju Pharma Co., Ltd. v. Sandoz Inc., 13-6608 (S.D.N.Y.) |
Sept. 18, 2013 |
Hon. Paul A. Crotty |
Istalol® |
6,335,335 6,645,963 |
Forest Labs., Inc. v. Apotex Corp., 13-1602 (D. Del.) |
Sept. 23, 2013 |
Hon. Sue L. Robinson |
Savella®(milnacipran hydrochloride tablets) |
6,602,911 7,888,342 7,994,220 |
Forest Labs., Inc. v. Hetero USA Inc., 13-1603 (D. Del.) |
Sept. 23, 2013 |
Hon. Sue L. Robinson |
Savella®(milnacipran hydrochloride tablets) |
6,602,911 7,888,342 7,994,220 |
Forest Labs., Inc. v. Lupin Ltd., 13-1604 (D. Del.) |
Sept. 23, 2013 |
Hon. Sue L. Robinson |
Savella®(milnacipran hydrochloride tablets) |
6,602,911 7,888,342 7,994,220 |
Forest Labs., Inc. v. Mylan Inc., 13-1605 (D. Del.) |
Sept. 23, 2013 |
Hon. Sue L. Robinson |
Savella®(milnacipran hydrochloride tablets) |
6,602,911 7,888,342 7,994,220 |
Forest Labs., Inc. v. Par Pharma. Inc., 13-1606 (D. Del.) |
Sept. 23, 2013 |
Hon. Sue L. Robinson |
Savella®(milnacipran hydrochloride tablets) |
6,602,911 7,888,342 7,994,220 |
Forest Labs., Inc. v. Ranbaxy Inc., 13-1607 (D. Del.) |
Sept. 23, 2013 |
Hon. Sue L. Robinson |
Savella®(milnacipran hydrochloride tablets) |
6,602,911 7,888,342 7,994,220 |
Pfizer Inc. v. Apotex Inc., 13-6962 (N.D. Ill.) |
Sept. 27, 2013 |
Hon. Marvin E. Aspen |
Tygacil®(tigecycline injectable IV infusion) |
8,372,995 |
Otsuka Pharma. Co., Ltd. v. Sandoz, Inc. 13-5788 (D.N.J.) |
Sept. 27, 2013 |
Hon. Freda L. Wolfson |
Busulfex®(busulfan injection) |
5,430,057 5,559,148 |
Galderma Labs., L.P. v. Perrigo Israel Pharma. Ltd., 13-3930 (N.D. Tex.) |
Sept. 27, 2013 |
Hon. David C Godbey |
Epiduo®Gel (adapalene / benzoyl peroxide) |
7,820,186 7,964,202 8,071,644 8,080,537 8,105,618 8,129,362 8,241,649 8,445,543 |
Helsinn Healthcare, S.A. v. Dr. Reddy’s Labs., Ltd., 13-5815 (D.N.J.) |
Sept. 30, 2013 |
Hon. Mary L. Cooper |
Aloxi®(palonosetron hydrochloride injection) |
8,518,981 |
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.